Effects of Vitamin D Supplementation in Atorvastatin‐Treated Patients: A New Drug Interaction With an Unexpected Consequence

@article{Schwartz2009EffectsOV,
  title={Effects of Vitamin D Supplementation in Atorvastatin‐Treated Patients: A New Drug Interaction With an Unexpected Consequence},
  author={Janice B Schwartz},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2009},
  volume={85}
}
  • J. Schwartz
  • Published 2009
  • Chemistry, Medicine
  • Clinical Pharmacology & Therapeutics
The objective of this study was to determine vitamin D supplementation effects on concentrations of atorvastatin and cholesterol in patients. Sixteen patients (8 men, 8 women; 10 Caucasians, 4 African Americans, 1 Hispanic, 1 Asian), aged 63 ± 11 years (mean ± SD, weight 92 ± 31 kg) on atorvastatin (45 ± 33 mg/day) were studied with and without supplemental vitamin D (800 IU/day for 6 weeks). Levels of vitamin D (1,25‐dihydroxy(OH) and 25 OH‐metabolites), atorvastatin (parent, OH‐acid… Expand
Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin
TLDR
A significant decrease in the level of cholesterol and triglyceride was showed in ST alone treated group, whereas VD alone failed to alter the blood lipid levels, suggesting that ST alone or in combination with VD does not produce any hepatotoxicity. Expand
Vitamin D Levels and Lipid Response to Atorvastatin
TLDR
It is suggested that vitamin D concentrations >30 nmol/L may be required for atorvastatin to reduce lipid levels in patients with acute myocardial infarction. Expand
Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin – a pilot study
TLDR
Results suggest that vitamin D3 supplementation (1000 IU per day) in human volunteers does not produce a P‐gp‐mediated drug interaction with orally administered digoxin. Expand
Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial.
TLDR
Vitamin D supplementation might improve serum lipid levels in statin-treated patients with hypercholesterolemia, it might be an adjuvant therapy for patients withHypercholesterolesmia, and vitamin D supplementation resulted in increased serum 25-hydroxyvitamin D concentrations compared with placebo. Expand
Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships.
TLDR
Vitamin D lipid-lowering effects appear limited to statin-treated patients and are likely due to decreased cholesterol absorption, suggesting the superiority of determining free 25-OH D levels compared to total 25- OH vitamin D levels when analyzing biologic responses. Expand
No Impact of Vitamin D on the CYP3A Biomarker 4β-Hydroxycholesterol in Patients with Abnormal Glucose Regulation
TLDR
Evidence is provided that vitamin D3 may not substantially affect hepatic CYP3A4 and the possibility of an impact of intestinal first-pass metabolism of orally administered drugs which should be investigated. Expand
Baseline Vitamin D Deficiency Decreases the Effectiveness of Statins in HIV-Infected Adults on Antiretroviral Therapy
TLDR
Although 25(OH)D did not change with rosuvastatin, baseline vitamin D deficiency decreased the effectiveness of rosuVastatin and vitamin D supplementation may be warranted for deficient patients initiating statin therapy. Expand
Serum Levels of 25-Hydroxyvitamin D and the CYP3A Biomarker 4β-Hydroxycholesterol in a High-Dose Vitamin D Supplementation Study
TLDR
A moderate, but statistically significant, negative correlation between CRP and 4β-hydroxycholesterol levels was observed, which supports earlier experimental results that inflammation may suppress hepatic CYP3A activity, a finding of potentially high clinical relevance that warrants further exploration. Expand
Influence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials
TLDR
The lipid modulating effects of vitamin D supplementation should be further investigated though large-scale, randomized trials with adequate doses which can effectively elevated the active form ofitamin D in plasma and with proper population which has hyperlipemia as an inclusion criterion. Expand
Vitamin D Supplementation and Endothelial Function in Vitamin D Deficient HIV-Infected Patients: A Randomized Placebo-Controlled Trial
TLDR
Among HIV-infected individuals with vitamin D deficiency, supplementation with 4,000 IU vitamin D3 daily for 12 weeks modestly improved vitamin D status and cholesterol but worsened insulin resistance without change in endothelial function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease.
TLDR
Vitamin D deficiency is a risk factor for osteoporosis and other chronic diseases, including type 1 diabetes, hypertension, metabolic syndrome, and ischemic heart disease, and atorvastatin increases vitamin D levels, which could explain some of the beneficial effects of atorVastatin at the cardiovascular level that are unrelated to cholesterol levels. Expand
Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials.
BACKGROUND Ecological and observational studies suggest that low vitamin D status could be associated with higher mortality from life-threatening conditions including cancer, cardiovascular disease,Expand
Vitamin D Deficiency and Risk of Cardiovascular Disease
TLDR
Vitamin D deficiency is associated with incident cardiovascular disease and further clinical and experimental studies may be warranted to determine whether correction of vitamin D deficiency could contribute to the prevention of cardiovascular disease. Expand
Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate
TLDR
A combination of higher plasma levels and increased intrinsic sensitivity explained the greater pharmacodynamic effects of triazolam in elderly subjects, and age‐dependent differences among women reached significance for observer‐rated sedation. Expand
Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
TLDR
It is indicated that atorvastatin treatment normalizes levels of all classes of triglyceride-rich lipoproteins and LDL in both the fasting and fed states in patients with CHD compared with control subjects. Expand
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
TLDR
Adding ezetimibe to ongoing statin therapy led to substantial additional reduction in LDL cholesterol levels, facilitating attainment of NCEP goals and offers a new therapeutic option for patients receiving statins who require further reduction in cholesterol levels. Expand
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.
TLDR
The clinical and in vitro data suggest that reduced free serum testosterone may have a modulatory role in age-dependent changes in zolpidem pharmacokinetics in men and recommendations of lower clinical doses of zolPidem in the elderly are consistent with recommendations. Expand
Clinical Pharmacokinetics of Atorvastatin
TLDR
Atorvastatin is subject to metabolism by CYP3A4 and cellular membrane transport by OATP C and P-glycoprotein, and drug-drug interactions with potent inhibitors of these systems, such as itraconazole, nelfinavir, ritonavir, cyclosporin, fibrates and grapefruit juice, have been demonstrated. Expand
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
TLDR
Atorvastatin was the most effective statin tested in lowering cholesterol in LDL, non-HDL, and RLP in the fasting and fed states, and getting patients with CHD to established goals. Expand
Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements.
TLDR
Data suggest that 1,25D(3)-dependent, VDR-mediated induction of CYP3A4 may constitute a chemoprotective mechanism for detoxification of enteric xenobiotics and carcinogens. Expand
...
1
2
3
4
...